Wei Tong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Tong has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Shenghui Lan
3 shared publicationsWei Chen
3 shared publicationsYuxiang Hu
3 shared publicationsZengwu Shao
3 shared publicationsZhipeng Dai
3 shared publicationsFenfei Zhao
2 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by KEAI Publishing in Fundamental Research
- Vol. 5 (4) , 1804-1821
Stem cell-derived small extracellular vesicles containing miR-27b-3p attenuated osteoarthritis through inhibition of leukaemia inhibitory factor
Mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) have been demonstrated to be an effective Cell-Free Therapy in the treatment of OA, but the precise target cells and response mechanisms are not well characterised. In this study, first, we found that intra-articular injection of human umbilical cord MSC (UCMSC)-derived sEVs (U-sEVs) significantly alleviated mouse OA. Then, U-sEVs were taken up rapidly and preferentially by fibroblast-like synoviocytes (FLSs) as well as cartilage superficial layer cells (SFCs) in a mouse model. Furthermore, significant increase in miR-27b-3p in those two cell types after U-sEV treatment was found by miRNA sequencing, identifying miR-27b-3p as a key cargo of U-sEVs. Bioinformatics and luciferase reporter found that leukaemia inhibitory factor (LIF) is the target gene of miR-27b-3p. Later, single-cell RNA-sequencing (scRNA-seq) and RNA-sequencing revealed that LIF could directly induce synovitis and cartilage erosion, possibly by promoting proinflammatory cytokine and MMPs expression. Based on this, miR-27b-3p-overexpressing U-sEVs inhibit the expression of LIF in both FLSs and SFCs, and accordingly exhibited stronger effects in mitigating synovitis, cartilage degeneration and OA progression compared to control U-sEVs. In conclusion, our results revealed that U-sEVs containing miR-27b-3p play a dominant role in relieving OA, largely by targeting LIF expression in FLSs and SFCs.
- 1 July 2025
- Published by KEAI Publishing in Fundamental Research
- Vol. 5 (4) , 1804-1821
Open AccessStem cell-derived small extracellular vesicles containing miR-27b-3p attenuated osteoarthritis through inhibition of leukaemia inhibitory factor
Mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) have been demonstrated to be an effective Cell-Free Therapy in the treatment of OA, but the precise target cells and response mechanisms are not well characterised. In this study, first, we found that intra-articular injection of human umbilical cord MSC (UCMSC)-derived sEVs (U-sEVs) significantly alleviated mouse OA. Then, U-sEVs were taken up rapidly and preferentially by fibroblast-like synoviocytes (FLSs) as well as cartilage superficial layer cells (SFCs) in a mouse model. Furthermore, significant increase in miR-27b-3p in those two cell types after U-sEV treatment was found by miRNA sequencing, identifying miR-27b-3p as a key cargo of U-sEVs. Bioinformatics and luciferase reporter found that leukaemia inhibitory factor (LIF) is the target gene of miR-27b-3p. Later, single-cell RNA-sequencing (scRNA-seq) and RNA-sequencing revealed that LIF could directly induce synovitis and cartilage erosion, possibly by promoting proinflammatory cytokine and MMPs expression. Based on this, miR-27b-3p-overexpressing U-sEVs inhibit the expression of LIF in both FLSs and SFCs, and accordingly exhibited stronger effects in mitigating synovitis, cartilage degeneration and OA progression compared to control U-sEVs. In conclusion, our results revealed that U-sEVs containing miR-27b-3p play a dominant role in relieving OA, largely by targeting LIF expression in FLSs and SFCs.
- Open Access
- 1 July 2022
- Published by Springer Nature in Research Square
Stem cell-derived small extracellular vesicles containing miR-27b-3p attenuated osteoarthritis by targeting leukaemia inhibitory factor expression of synoviocytes
Mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) have been demonstrated to be effective in the treatment of OA, but the precise target cells and response mechanisms are not well characterised. In this study, first, we found that intra-articular injection of human umbilical cord MSC (UCMSC)-derived sEVs (U-sEVs) significantly alleviated mouse OA. Then, U-sEVs were taken up rapidly and preferentially by fibroblast-like synoviocytes (FLSs) in a mouse model. Furthermore, significant increase in miR-27b-3p in FLSs after U-sEV treatment were found by miRNA sequencing, identifying miR-27b-3p as a key cargo of U-sEVs. Bioinformatics and luciferase reporter found that leukaemia inhibitory factor (LIF) is the target gene of miR-27b-3p, and single-cell RNA-sequencing (scRNA-seq) and RNA-sequencing revealed that LIF could directly induce synovitis, possibly by promoting proinflammatory cytokine and MMPs expression. Lastly, both miR-27b-3p and miR-27b-3p-overexpressing U-sEVs inhibit the expression of LIF in FLSs, and accordingly exhibited stronger effects in mitigating synovitis and OA progression compared to control U-sEVs. In conclusion, our results revealed that the main recipient cell of U-sEVs in the joints are FLSs. Mechanistically, miR-27b-3p in U-sEVs inhibited LIF expression of FLSs, and thus inhibited synovitis and delayed OA.
- 1 July 2022
- Published by Springer Nature in Research Square
Open AccessStem cell-derived small extracellular vesicles containing miR-27b-3p attenuated osteoarthritis by targeting leukaemia inhibitory factor expression of synoviocytes
Mesenchymal stem cell (MSC)-derived small extracellular vesicles (sEVs) have been demonstrated to be effective in the treatment of OA, but the precise target cells and response mechanisms are not well characterised. In this study, first, we found that intra-articular injection of human umbilical cord MSC (UCMSC)-derived sEVs (U-sEVs) significantly alleviated mouse OA. Then, U-sEVs were taken up rapidly and preferentially by fibroblast-like synoviocytes (FLSs) in a mouse model. Furthermore, significant increase in miR-27b-3p in FLSs after U-sEV treatment were found by miRNA sequencing, identifying miR-27b-3p as a key cargo of U-sEVs. Bioinformatics and luciferase reporter found that leukaemia inhibitory factor (LIF) is the target gene of miR-27b-3p, and single-cell RNA-sequencing (scRNA-seq) and RNA-sequencing revealed that LIF could directly induce synovitis, possibly by promoting proinflammatory cytokine and MMPs expression. Lastly, both miR-27b-3p and miR-27b-3p-overexpressing U-sEVs inhibit the expression of LIF in FLSs, and accordingly exhibited stronger effects in mitigating synovitis and OA progression compared to control U-sEVs. In conclusion, our results revealed that the main recipient cell of U-sEVs in the joints are FLSs. Mechanistically, miR-27b-3p in U-sEVs inhibited LIF expression of FLSs, and thus inhibited synovitis and delayed OA.
- Top Cited PapersOpen Access
- 1 January 2022
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (10) , 3961-3980
Mechanosensitive Piezo1 is crucial for periosteal stem cell-mediated fracture healing
The biomechanical environment plays a dominant role in fracture healing, and Piezo1 is regarded as a major mechanosensor in bone homeostasis. However, the role of Piezo1 in fracture healing is not yet well characterized. In this study, we first delineated that Piezo1 is highly expressed in periosteal stem cells (PSCs) and their derived osteoblastic lineage cells and chondrocytes. Furthermore, downregulation of Piezo1 in callus leads to impaired fracture healing, while activation by its specific agonist promotes fracture healing through stimulation of PSC-modulated chondrogenesis and osteogenesis, along with accelerated cartilage-to-bone transformation. Interestingly, vascular endothelial growth factor A is upregulated after Yoda1 treatment of PSCs, indicating an indirect role of Piezo1 in angiogenesis. Mechanistically, activation of Piezo1 promotes expression of Yes-associated protein (YAP) and its nuclear localization in PSCs, which in turn increases the expression and nuclear localization of β-catenin. In detail, YAP directly interacts with β-catenin in the nucleus and forms a transcriptional YAP/β-catenin complex, which upregulates osteogenic, chondrogenic and angiogenic factors. Lastly, Yoda1 treatment significantly improves fracture healing in a delayed union mouse model generated by tail suspension. These findings indicate that Piezo1 is a potential therapeutic target for fracture delayed union or nonunion.
- 1 January 2022
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 18 (10) , 3961-3980
Top Cited PapersOpen AccessMechanosensitive Piezo1 is crucial for periosteal stem cell-mediated fracture healing
The biomechanical environment plays a dominant role in fracture healing, and Piezo1 is regarded as a major mechanosensor in bone homeostasis. However, the role of Piezo1 in fracture healing is not yet well characterized. In this study, we first delineated that Piezo1 is highly expressed in periosteal stem cells (PSCs) and their derived osteoblastic lineage cells and chondrocytes. Furthermore, downregulation of Piezo1 in callus leads to impaired fracture healing, while activation by its specific agonist promotes fracture healing through stimulation of PSC-modulated chondrogenesis and osteogenesis, along with accelerated cartilage-to-bone transformation. Interestingly, vascular endothelial growth factor A is upregulated after Yoda1 treatment of PSCs, indicating an indirect role of Piezo1 in angiogenesis. Mechanistically, activation of Piezo1 promotes expression of Yes-associated protein (YAP) and its nuclear localization in PSCs, which in turn increases the expression and nuclear localization of β-catenin. In detail, YAP directly interacts with β-catenin in the nucleus and forms a transcriptional YAP/β-catenin complex, which upregulates osteogenic, chondrogenic and angiogenic factors. Lastly, Yoda1 treatment significantly improves fracture healing in a delayed union mouse model generated by tail suspension. These findings indicate that Piezo1 is a potential therapeutic target for fracture delayed union or nonunion.